Supplementary Figure 5 from A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors
Puntos clave
Los puntos clave no están disponibles para este artículo en este momento.
Resumen
Supplemental Figure 5 - Somatic Mutation Profiles in Baseline ctDNA
Supplementary Figure 5 from A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors | Synapse